Overview

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Phase:
PHASE2
Details
Lead Sponsor:
Avidity Biosciences, Inc.